Skip to main content

Table 3 Cox regression analysis for LUAD patients harboring KRAS mutations

From: Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients

Covariates A. K-Ras4A expression Covariates B. K-Ras4A proportion
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HRa
(95% CIb)
p-value HR
(95% CI)
p-value HR
(95% CI)
p-value HR
(95% CI)
p-value
Age (≥65 years) 1.326 (0.761−2.312) 0.320 1.351 (0.735−2.480) 0.333 Age (≥65 years) 1.326 (0.761−2.312) 0.320 1.443 (0.778−2.678) 0.245
Gender (Male) 1.536 (0.891−2.650) 0.123 1.734 (0.954−3.152) 0.0711 Gender (Male) 1.536 (0.891−2.650) 0.123 1.690 (0.911−3.061) 0.0971
Smoking history 1.076 (0.804−1.440) 0.622 1.168 (0.851−1.602) 0.337 Smoking history 1.076 (0.804−1.440) 0.622 1.191 (0.866−1.638) 0.282
KRAS amplification (Not amplified) 0.820 (0.410−1.643) 0.576 0.802 (0.383−1.679) 0.558 KRAS amplification (Not amplified) 0.820 (0.410−1.643) 0.576 0.954 (0.448−2.031) 0.903
K-Ras4A expression (low) 1.986 (1.131−3.490) 0.017 2.533 (1.380−4.651) 2.72E-3 K-Ras4A proportion (low) 2.258 (1.295−3.938) 4.10E-3 2.549 (1.387−4.684) 2.58E-3
Pathological stage (III/IV) 3.088 (1.747−5.459) 1.05E-4 3.268 (1.793−5.954) 1.10E-4 Pathological stage (III/IV) 3.088 (1.747−5.459) 1.05E-4 3.404 (1.867−6.207) 6.41E-5
  1. aHR, hazard ratio
  2. bCI, confidence interval